美国预防服务工作组推荐声明:心电图为房颤筛查
美国预防服务工作组(USPSTF)针对≥65岁成人以心电图筛查房颤的获益与危害进行证据审查,并比较心电图筛查与常规照护对既往未诊断房颤的检出效果,以及筛查检出房颤后抗凝或抗血小板治疗的获益与危害。工作组发现多数既往未诊断房颤的老年人卒中风险已超过抗凝治疗阈值、符合治疗条件,抗凝对高卒中风险的有症状房颤患者卒中预防有效;但无证据确定对无症状成人筛查后治疗是否优于常规照护,而异常心电图引发的诊断随访与治疗危害(包括误诊和有创检查)已明确。因这些不确定性,无法确定心电图筛查的净获益,最终给出 I 声明。
要点
- USPSTF 对≥65岁成人以心电图筛查房颤给出 I 声明:当前证据不足以评估获益与危害的平衡。
- 多数既往未诊断房颤的老年人卒中风险已超过抗凝治疗阈值、符合治疗条件。
- 抗凝治疗对高卒中风险的有症状房颤患者卒中预防有效。
- 无证据确定对无症状成人筛查后治疗是否优于常规照护。
- 异常心电图引发的诊断随访与治疗危害已明确,包括误诊和有创检查。
适用人群与场景
- 证据审查人群为65岁及以上成人,评估以心电图筛查房颤的获益与危害。
- 讨论的筛查对象包括无症状成人;有症状房颤患者抗凝治疗获益有证据支持。
研究设计与关键结果
- USPSTF 审查了65岁及以上成人以心电图筛查房颤的获益与危害、心电图筛查对比常规照护检出既往未诊断房颤的效果,以及筛查检出房颤后抗凝或抗血小板治疗的获益与危害。
- 多数既往未诊断房颤的老年人卒中风险高于抗凝治疗阈值,符合治疗条件。
- 抗凝治疗对高卒中风险的有症状房颤患者卒中预防有效。
- USPSTF 发现证据不足,无法确定对无症状成人以心电图筛查并随后治疗是否比常规照护更有效。
- 异常心电图结果引发的诊断随访与治疗危害已明确,包括误诊和有创检查。
- 因上述不确定性,无法确定心电图筛查的净获益。
证据类型、等级与局限
- 证据类型:美国预防服务工作组(USPSTF)推荐声明,基于对相关证据的系统审查。
- 推荐强度:I 声明(当前证据不足以评估获益与危害的平衡)。
- 局限:原文未报告局限性
对床旁实践的改变
- USPSTF 结论为当前证据不足以评估≥65岁成人以心电图筛查房颤的获益与危害平衡(I 声明),原文未据此给出筛查推荐。
- 原文指出异常心电图引发的诊断随访与治疗危害已明确,包括误诊和有创检查。
- 原文指出抗凝治疗对高卒中风险的有症状房颤患者卒中预防有效,但无证据确定对无症状成人筛查后治疗是否优于常规照护。
指南或共识出处
- US Preventive Services Task Force Recommendation Statement: Screening for Atrial Fibrillation With Electrocardiography(JAMA)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Atrial fibrillation is the most common type of cardiac arrhythmia (irregular heartbeat), and its prevalence increases with age, affecting about 3% of men and 2% of women aged 65 to 69 years and about 10% of adults 85 years and older. Atrial fibrillation is a major risk factor for ischemic stroke, increasing risk of stroke by as much as 5-fold. Approximately 20% of patients who have a stroke associated with atrial fibrillation are first diagnosed with atrial fibrillation at the time of stroke or shortly thereafter.
OBJECTIVE: To issue a new US Preventive Services Task Force (USPSTF) recommendation on screening for atrial fibrillation with electrocardiography (ECG).
EVIDENCE REVIEW: The USPSTF reviewed the evidence on the benefits and harms of screening for atrial fibrillation with ECG in adults 65 years and older, the effectiveness of screening with ECG for detecting previously undiagnosed atrial fibrillation compared with usual care, and the benefits and harms of anticoagulant or antiplatelet therapy for the treatment of screen-detected atrial fibrillation in older adults.
FINDINGS: Most older adults with previously undiagnosed atrial fibrillation have a stroke risk above the threshold for anticoagulant therapy and would be eligible for treatment. Anticoagulant therapy is effective for stroke prevention in symptomatic persons with atrial fibrillation and high stroke risk. However, the USPSTF found inadequate evidence to determine whether screening with ECG and subsequent treatment in asymptomatic adults is more effective than usual care. At the same time, the harms of diagnostic follow-up and treatment prompted by abnormal ECG results are well established and include misdiagnosis and invasive testing. Given these uncertainties, it is not possible to determine the net benefit of screening with ECG.
CONCLUSIONS AND RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation with ECG. (I statement).
参考来源
- Curry SJ, Krist AH, Owens DK, et al. Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. JAMA. 2018. PMID: 30088016. doi:10.1001/jama.2018.10321
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。